Novo Nordisk’s Oral Semaglutide Demonstrates Potential to be the First Oral GLP-1 RA Therapy for Children and Adolescents with Type 2 Diabetes

Follow Drugslib on

Bagsværd, Denmark, 23 April 2026 – Novo Nordisk today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 diabetes in children and adolescents aged 10–17 years with type 2 diabetes. Oral semaglutide demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo in the trial and showed a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials. Oral semaglutide is available today as Rybelsus® in the EU and US and will be available in the US as Ozempic® pill soon.

  • PIONEER TEENS is the first clinical trial of an oral GLP-1 RA therapy in children and adolescents aged 10–17 years with type 2 diabetes, addressing a significant unmet need.
  • The trial demonstrated a statistically significant and superior reduction in blood sugar by 0.83% vs placebo at 26 weeks.
  • Novo Nordisk expects to file for regulatory approval of a label expansion for Ozempic® pill and Rybelsus® in the US and EU in the second half of the year.

    • “Over the past two decades, the prevalence of type 2 diabetes among children and adolescents has increased substantially, yet treatment options for this population remain limited, underscoring a significant unmet need. Oral semaglutide has already demonstrated clinically meaningful glycaemic efficacy and a well-established safety profile in adults with type 2 diabetes, alongside proven cardiovascular benefits unique to this molecule,” said Martin Holst Lange, chief scientific officer and executive vice president, Research & Development, at Novo Nordisk. “These results from the PIONEER TEENS trial confirm that oral semaglutide is an effective treatment option for children and adolescents with type 2 diabetes who require glycaemic control beyond that provided by the current standard of care.”

    Type 2 diabetes in children and adolescents is a severe and progressive condition that is strongly associated with increased risks of early mortality in adulthood. Current management for glycaemic control in youth-onset type 2 diabetes remains constrained, and there is an unmet need for more treatment options. In 2021, 14.6 million adolescents were living with type 2 diabetes globally. By 2030, this number is projected to increase to 20.9 million1-3.

    Current guidelines recommend metformin and insulin as first-line treatments4,5 ; however, metformin is associated with failure in glycaemic control in approximately half of adolescents13, and insulin is associated with hypoglycaemia and weight gain4,5. This is the first clinical trial of an oral GLP-1 RA therapy in this age group, addressing a critical unmet need. Pending regulatory approvals, oral semaglutide has the potential to be the first and only oral GLP-1 RA to demonstrate superior glycemic efficacy versus placebo in children and adolescents with type 2 diabetes, while maintaining the well-established safety profile seen across the semaglutide portfolio.

    About the PIONEER TEENS TrialPIONEER TEENS (NCT04596631) was a 52-week, randomised, double-blind, placebo-controlled phase 3a trial evaluating oral semaglutide at maximum tolerated doses (3 mg, 7 mg, or 14 mg once daily) vs placebo in 132 children and adolescents aged 10–17 years with type 2 diabetes. The participants received background treatment with metformin, basal insulin or both. The primary endpoint was change from baseline to week 26 in HbA1c6 .

    About oral semaglutide in type 2 diabetesOral semaglutide in type 2 diabetes (available today as Rybelsus® in the EU and US; launching in the US as Ozempic® pill later in Q2 2026) is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise. Oral semaglutide in type 2 diabetes is administered once daily. Two bioequivalent tablet formulations exist: 1.5 mg, 4 mg, and 9 mg (round tablets, second generation) and 3 mg, 7 mg, and 14 mg (oval tablets, first generation). In addition, 25 mg and 50 mg tablets are approved in the EU for type 2 diabetes7,8. Oral semaglutide offers superior blood glucose lowering versus multiple comparators9,10, together with consistent weight reduction9,10,11, reduction in cardiometabolic risk factors11 and reduction in major adverse cardiovascular events (MACE).12 Oral semaglutide is not currently approved for use in children or adolescents.

    Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.References

  • Perng W, et al. Diabetes Care. 2023;46(3):490-9
  • Wu H, et al. Diabetes Res Clin Pract. 2022 Mar;185:109785
  • Chen X, et al. BMC Med. 2025 Jan 29;23(1):48
  • Shah AS, et al. Horm Res Paediatr. 2024;97(6):555-583
  • American Diabetes Association Professional Practice Committee for Diabetes-2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S297–S320
  • ClinicalTrials.gov. A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (PIONEER TEENS). Available at: https://clinicaltrials.gov/study/NCT06221969. Last accessed: April 2026
  • Rybelsus® (oral semaglutide): US Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s023lbl.pdf. Last accessed: April 2026
  • Rybelsus® (oral semaglutide): Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/rybelsus. Last accessed: April 2026
  • Rosenstock J, et al. JAMA. 2019;321(15):1466-1480.
  • Rodbard HW, et al. Diabetes Care. 2019;42(12):2272-2281.
  • Husain M, et al. N Engl J Med. 2019;381(9):841-851.
  • McGuire DK, et al. N Engl J Med. 2025;392(20):2001-2012.

    • Source: Novo Nordisk

    Source: HealthDay

    Related articles

  • Novo Nordisk Introduces Ozempic Pill; Available in the US Q2 2026 - February 4, 2026
  • FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease - January 28, 2025
  • Novo Nordisk Receives FDA Approval of Higher-Dose Ozempic 2 mg Providing Increased Glycemic Control for Adults with Type 2 Diabetes - March 28, 2022
  • FDA Approves Ozempic (semaglutide) for Cardiovascular Risk Reduction in Adults with Type 2 Diabetes and Known Heart Disease - January 16, 2020
  • Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes - December 5, 2017
  • Novo Nordisk Receives Positive 16-0 vote from FDA Advisory Committee in Favor of Approval for Semaglutide - October 18, 2017
  • Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes - December 5, 2016

    • Ozempic (semaglutide) FDA Approval History

    More news resources

  • FDA Medwatch Drug Alerts
  • Daily MedNews
  • News for Health Professionals
  • New Drug Approvals
  • New Drug Applications
  • Clinical Trial Results
  • Generic Drug Approvals
  • Drugs.com Podcast

    • Subscribe to our newsletter

    Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

    Posted : 2026-04-24 09:13

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords